Davita Inc vs Tenaris S.A. American Depositary Shares — how do they compare? Davita Inc trades at $180.7 (market cap $11.62B), while Tenaris S.A. American Depositary Shares trades at $57.88 (market cap $29.31B). The key difference: Tenaris S.A. American Depositary Shares is far larger — about 2.5× Davita Inc's market cap, and Tenaris S.A. American Depositary Shares pays a 4.07% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Tenaris S.A. American Depositary Shares for 0 Days on average.
| DVA | TS | |
|---|---|---|
Market Cap | $11.62B | $29.31B |
Volume | 400,903 | 802,043 |
Sector | Health | Energy |
52-Week High | $240.96 | $64.02 |
52-Week Low | $103.87 | $34.28 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.33B | $26.97B |
Dividend Yield | — | 4.07% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $180.70, down 0.59% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 15.43 P/E ratio. The stock shows bullish technical signals with moving averages supporting upward momentum, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents compelling value with analyst consensus target of $235.67 offering 30% upside potential, supported by Warren Buffett's substantial ownership. Key risks include rising debt-to-asset ratio reaching 65.55% and regulatory pressures in healthcare. The combination of earnings momentum, institutional support, and reasonable valuation creates favorable investment conditions despite margin compression concerns.
Tenaris (TS) trades at $58.54, up 0.84% with neutral technical signals and strong fundamental metrics including a P/E of 15.65 and net income margin of 15.88%. Recent earnings beats and a $1.18 dividend support investor confidence, though cash flow trends show modest net outflows. The stock faces near-term headwinds from shipment delays and margin compression as noted in recent analyst reports.
The outlook remains balanced with analyst consensus favoring Buy (57.69%) and a $66.67 price target suggesting 14% upside. Key risks include cyclical energy sector exposure and operational disruptions, but solid profitability and valuation support make TS attractive for dividend and value investors seeking energy sector exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Tenaris S.A. manufactures seamless and welded steel pipe products, including casing, tubing, and line pipe, for the oil and gas industry and certain industrial applications. The company operates an integrated production network across 17 countries and offers Rig Direct, its integrated supply-chain service for oilfield customers.
Read more on TS →